NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

AtaiBeckley Inc. (ATAI) Stock Analysis

AtaiBeckley Inc. (ATAI) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ATAI

$7.39

+$0.05 (+0.68%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ATAI with… →

ATAI Key Statistics

As of Sep 4, 2026
Trading
Open
$7.34
Previous Close
$7.34
Day's Range
7.31–7.41
52-Week Range
3.27–7.45
Volume
10.31M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.55
Valuation
Market Cap
$2.74B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
612.86
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.81
Financials (FY)
Revenue (FY)
$4.09M+1227.60%
Net Income (FY)
−$660.05M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
370.86M
1-Year Return
+62.06%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
12.33M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ATAI Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+80.68%
2025+207.52%
2024−5.67%
2023−46.99%
2022−65.14%
2021 (partial year)−60.77%

As of September 4, 2026.

ATAI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$4.09M−$660.05M−16142.0%
2024$308.00K−$149.27M−48464.0%
2023$314.00K−$40.22M−12810.2%
2022$233.00K−$152.39M−65401.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$4.09M—−$113.35M−$660.05M−16142.0%
2024$308.00K—−$102.17M−$149.27M−48464.0%
2023$314.00K—−$123.03M−$40.22M−12810.2%
2022$233.00K—−$144.43M−$152.39M−65401.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ATAI Valuation vs Biotechnology Median

Median of 656 stocks
MetricATAIBiotechnology medianvs median
P/S ratio612.8615.2640.2x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

AtaiBeckley Inc. (ATAI) carries a market capitalisation of $2.74B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 99 employees.

The most recent close on file for ATAI is $7.39, dated September 4, 2026. That is +$0.05 (+0.68%) against the previous close. Over the past 52 weeks the price has ranged from $3.27 to $7.45. The latest close sits 126.34% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $4.09M. That is +1,227.60% against the prior fiscal year, when revenue was $308.00K. The same year closed with a net loss of $660.05M. The reported profit margin is 0%. Trailing earnings per share are −2.81.

Across the 4 fiscal years on file, revenue moves from $233.00K in 2022 to $4.09M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 612.86 times revenue. On price-to-sales that is 40.2 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is +62.06%. Across 5 years the annualized return works out at −15.51%. Beta against the wider market is reported at 1.55. Daily returns over the trailing 5 years annualize to a volatility of 84.96%.

Growth & Income

The record shows no dividend for ATAI.

2026 is still running; the price is +80.68% year to date. The strongest complete calendar year on file is 2025 at +207.52%; the weakest is 2022 at −65.14%. Of the 4 complete calendar years on file, 1 finished higher.

Peer Comparison

AtaiBeckley Inc. (ATAI) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
AtaiBeckley Inc. ATAI $2.74B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. AtaiBeckley Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About AtaiBeckley Inc.

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York.

Visit website →